Last reviewed · How we verify
EVKEEZA (EVINACUMAB-DGNB)
EVKEEZA (generic name: EVINACUMAB-DGNB) is a Angiopoietin-like 3 Inhibitor [EPC] drug developed by REGENERON PHARMACEUTICALS. It is currently FDA-approved for Homozygous familial hypercholesterolemia.
At a glance
| Generic name | EVINACUMAB-DGNB |
|---|---|
| Sponsor | REGENERON PHARMACEUTICALS |
| Drug class | Angiopoietin-like 3 Inhibitor [EPC] |
| Target | Angiopoietin-related protein 3 |
| Therapeutic area | Metabolic |
| Phase | FDA-approved |
Approved indications
- Homozygous familial hypercholesterolemia
Common side effects
- Nasopharyngitis
- Influenza-like illness
- Dizziness
- Rhinorrhea
- Nausea
- Fatigue
- Infusion reactions
- Pain in extremity
- Asthenia
- Constipation
- Upper respiratory tract infection
- Nasal congestion
Serious adverse events
- Anaphylaxis
Key clinical trials
- A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Evinacumab in Patients With Severe Hypertriglyceridemia for the Prevention of Recurrent Acute Pancreatitis (Phase 2)
- NCT06500598 (N/A)
- A Three-Part, Single-Arm, Open-Label Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Evinacumab in Pediatric Patients With Homozygous Familial Hypercholesterolemia (Phase 3)
- A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamic Effects of ANGPTL3 Inhibition With Either Small-Interfering RNA Alone (Phase 2)
- An Open-Label Study to Evaluate the Long-Term Safety and Efficacy of Evinacumab in Patients With Homozygous Familial Hypercholesterolemia (Phase 3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- EVKEEZA CI brief — competitive landscape report
- EVKEEZA updates RSS · CI watch RSS
- REGENERON PHARMACEUTICALS portfolio CI
Frequently asked questions about EVKEEZA
What is EVKEEZA?
EVKEEZA (EVINACUMAB-DGNB) is a Angiopoietin-like 3 Inhibitor [EPC] drug developed by REGENERON PHARMACEUTICALS, indicated for Homozygous familial hypercholesterolemia.
What is EVKEEZA used for?
EVKEEZA is indicated for Homozygous familial hypercholesterolemia.
Who makes EVKEEZA?
EVKEEZA is developed and marketed by REGENERON PHARMACEUTICALS (see full REGENERON PHARMACEUTICALS pipeline at /company/regeneron).
What is the generic name of EVKEEZA?
EVINACUMAB-DGNB is the generic (nonproprietary) name of EVKEEZA.
What drug class is EVKEEZA in?
EVKEEZA belongs to the Angiopoietin-like 3 Inhibitor [EPC] class. See all Angiopoietin-like 3 Inhibitor [EPC] drugs at /class/angiopoietin-like-3-inhibitor-epc.
What development phase is EVKEEZA in?
EVKEEZA is FDA-approved (marketed).
What are the side effects of EVKEEZA?
Common side effects of EVKEEZA include Nasopharyngitis, Influenza-like illness, Dizziness, Rhinorrhea, Nausea, Fatigue. Serious adverse events: Anaphylaxis.
What does EVKEEZA target?
EVKEEZA targets Angiopoietin-related protein 3 and is a Angiopoietin-like 3 Inhibitor [EPC].
Related
- Drug class: All Angiopoietin-like 3 Inhibitor [EPC] drugs
- Target: All drugs targeting Angiopoietin-related protein 3
- Manufacturer: REGENERON PHARMACEUTICALS — full pipeline
- Therapeutic area: All drugs in Metabolic
- Indication: Drugs for Homozygous familial hypercholesterolemia
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing